Navigation Links
Novel method could improve the performance of proteins used therapeutically
Date:3/9/2011

FINDINGS: Whitehead Institute scientists have created a method that uses the enzyme sortase A to site-specifically modify proteins. Using this technique, researchers were able to increase potency, slow the metabolism, and improve thermal stability of several proteins, including interferon alpha 2 (IFN-alpha 2) and granulocyte colony-stimulating factor 3 (GCSF-3). IFN-alpha 2 is used to treat a variety of diseases, including leukemia, melanoma, and chronic hepatitis C, while GCSF-3 (known as filgrastim and marketed as Neupogen) is administered to patients with neutropenia.

RELEVANCE: Sortase could be used to improve other proteins used as therapeutics, for example those with IFN-alpha 2's characteristic four-helix bundle structure. Such proteins include erythropoietin (EPO), interleukin (IL) 2 (known as aldesleukin and marketed as Proleukin), IL-4, IL-7, IL9-, and IL-15. This same strategy could likely be applied to other therapeutically important proteins, but with a different folding pattern, as well.

Novel method could improve the performance of proteins used therapeutically

CAMBRIDGE, Mass. (March 9, 2011) Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.

The method, reported this month in Proceedings of the National Academy of Sciences (PNAS), uses the enzyme sortase A and can be applied to tailor proteins that possess a structure found in IFN-alpha 2, referred to as a four-helix bundle. Such proteins include erythropoietin (EPO), granulocyte colony-stimulating factor 3 (GCSF-3, known as filgrastim and marketed as Neupog
'/>"/>

Contact: Nicole Giese
giese@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Synthetic biology: TUM researchers develop novel kind of fluorescent protein
2. Team creates novel vaccine that produces strong immunity against cocaine high
3. Novel compounds show early promise in treatment of Parkinsons, Huntingtons, Alzheimers
4. GEN co-sponsors roundtable discussion on novel bioremediation techniques
5. In the lab, engineers novel liquid provides a solid fix for broken bones
6. Novel services for tropical forest monitoring with satellite
7. In new novel, secret discovery threatens company and damages love affair
8. Dow Agrosciences licenses exclusive novel crop enhancement technology
9. Novel regulatory process for T cells may help explain immune system diseases
10. Novel protein critical for cellular proliferation discovered
11. Novel reference material to standardize gene therapy applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... approach to genetic engineering drastically reduces the time ... bacteria, the workhorses of biotechnology, scientists are reporting. ... , the method paves the way for more ... environmental cleanup and other activities. , Keith Shearwin ... piece of the genetic material DNA into a ...
(Date:5/22/2013)... responsible for legionellosis, an infectious disease that can lead ... has developed a complex method enabling it to camouflage ... these acting against the infectious bacteria. , Research led ... which teams from the National Institute of Health (NIH) ... Barcelona (BSC) have also participated, has described for the ...
(Date:5/22/2013)... insects and wild plants have slowed in recent years, ... the University of Leeds and the Naturalis Biodiversity Centre ... in the diversity of species in Britain, Belgium and ... the picture brightened markedly after 1990, with a slowdown ... and wild plants. , Professor Bill Kunin, ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... An international team of researchers has studied the coralline algae ... Mediterranean Sea between 7.24 and 5.3 million years ago. Mediterranean ... following the isolation of the Mediterranean from the Indian Ocean ... The research team from the University of Granada ...
... Radiology 2009 Standards Division Guidelines" is the subject ... of the Journal of Vascular and Interventional ... and allied health professionals dedicated to improving public ... therapeutic interventionsprovides a unique collection of new (such ...
... from a one-of-a-kind, patient-driven effort to provide lung tissue ... idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and ... sustain them until life-saving transplants can be performed. ... of medicine, computational biology and pathology, and director of ...
Cached Biology News:Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 3Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients 2Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients 3
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Selexis SA , a Swiss-based biotechnology company with ... yield and stable mammalian cell lines ... completed the sequencing of their proprietary Chinese hamster ovary ... project was performed in collaboration with the Institute ...
... Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... medicine, announced today that China,s State Intellectual Property Office ... broad intellectual property protection in China for the manufacturing ... from human embryonic stem cells (hESCs).   ...
... polymer solution equal the energy output and otherwise outperform platinum ... University engineers has found. The researchers are certain that ... the other advantages by matching the best nanotube layout and ... technique can knock down one of the major roadblocks to ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Cheap catalyst made easy 2
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: